Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4...
Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with...
Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
1. Progression-free survival was not reached in the selpercatinib group and was 16.8 months in the control group, with an...
Amivantamab Plus Chemotherapy with and without Lazertinib in EGFR-mutant NSCLC
1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3 months for the amivantamab–lazertinib–chemotherapy group, and 4.2 months for...
Selpercatinib vs Chemotherapy and Pembrolizumab in RET Positive NSCLC
1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ±...
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1. Median progression-free survival was 11.4 months in the amivantamab–chemotherapy group and 6.7 months in the chemotherapy group with HR...
Berzosertib Plus Topotecan vs Topotecan Alone in Relapsed Small Cell Lung Cancer
1 .The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was...
Maintenance Olaparib Rechallenge in Platinum-Sensitive Relapsed Ovarian Cancer
1. Median PFS was improved in the olaparib arm vs placebo, with an HR 0.57 in the BRCAm cohort and...
Atezolizumab, Vemurafenib, and Cobimetinib in Melanoma With CNS Metastases
1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort and 27% in the BRAFV600 wild-type cohort....
Prophylactic Radiation Therapy for High-Risk Asymptomatic Bone Metastases
1. The hazard ratio of skeletal-related events in patients treated with radiation compared with patients who were not treated with...
